Cambridge Healthtech Institute’s 3rd Annual
Safety and Efficacy of Bispecific Antibodies, ADCs, and Combination Therapies
Enhancing Safety and Creating Synergies with Novel Therapeutic Modalities
11 November 2025
Novel bispecific and multispecific antibodies, antibody-drug conjugates (ADCs), and combination treatments open the door to addressing a broader set of clinical indications. Alongside these developments come new challenges in optimising safety and efficacy of these next-generation therapeutics. At PEGS Europe, Cambridge Healthtech Institute’s 3rd Annual Safety and Efficacy of Bispecific Antibodies, ADCs, and Combination Therapies conference will highlight novel therapeutic candidates and how researchers are mitigating toxicity, managing combination therapies, reducing off-target effects, and addressing challenges in treatment of solid tumours. This meeting will complement topics in bispecific antibody discovery and engineering for meeting unmet clinical needs.
Coverage will include, but is not limited to:
- Novel and emerging drug candidates and associate safety and efficacy profiles
- Addressing challenges in bispecific antibodies for solid tumours
- Expanding targets for bispecific ADCs
- The role of bispecific formats in safety and efficacy
- Creating synergies with combination therapies and avoiding overlapping toxicities
- Defining dose escalation recommendations
- Comparing differences in bispecific antibodies, multispecific antibodies, ADCs, and combination therapies
- Strategic target-based therapeutic development
The deadline for priority consideration is 28 March 2025.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: